Clinical Trial Update: Ivosidenib as Post-HSCT Maintenance for AML [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Ivosidenib as post-transplant maintenance in patients with IDH1-mutant acute myeloid leukemia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: IDH1 Mutation, Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING